Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial
- 30 August 2025
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (6) , 719-730
Abstract
Background and Aims: Despite current antithrombotic treatments, the recurrence of ischaemic events remains high in patients with diabetes mellitus (DM) or aspirin resistance after acute coronary syndrome (ACS). Whether twice-daily aspirin dosing reduces major adverse cardiovascular events (MACE) in this population remains unknown. Methods: In this prospective multicentre, randomized trial, patients with ACS and DM or high-risk of aspirin resistance (HRAR) defined as: (i) an index event occurring while on aspirin; (ii) body mass index ≥27 kg/m2; or (iii) increased waist circumference were assigned to receive enteric-coated aspirin once daily (100 mg/day) or twice daily (100 mg morning and evening). The primary outcome was MACE, a composite of any death, myocardial infarction, stroke, urgent coronary revascularization, stent thrombosis, or acute arterial thrombotic event assessed using a time-to-first-event analysis. The main secondary outcome was major bleeding (Bleeding Academic Research Consortium type 3–5). Results: In total, 2484 participants were enrolled (77.2% with DM, 55.5% with ST-elevation segment myocardial infarction). The median follow-up duration was 18 (interquartile range: 17.6–18.3) months. The primary outcome occurred in 95 of 1228 participants (7.7%) in the twice-daily aspirin group, and 110 of 1256 (8.8%) in the once-daily group (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.69–1.19; P = .42). Major bleeding rates were similar between the groups (1.9% vs 2.1%; HR 0.88; 95% CI 0.50–1.55). Conclusions: In patients with ACS and DM or HRAR, twice-daily aspirin did not significantly reduce the risk of MACE compared to once-daily dosing. No significant difference was observed in major bleeding between groups. Trial Registration: NCT02520921/EUDRACT No: 2015-000947-18.Keywords
Funding Information
- Programme Hospitalier de Recherche Clinique (PHRC14-1005)
- French Ministry of Health
- Bayer France and Biosensors
- Assistance Publique — Hôpitaux de Paris
This publication has 43 references indexed in Scilit:
- Aspirin for Secondary Prevention of Atherosclerosis—Evidence or Dogma?JAMA Cardiology, 2025
- Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trialAmerican Journal of Hematology, 2024
- Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular DiseaseJAMA Cardiology, 2023
- Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-AnalysisAmerican Journal of Cardiovascular Drugs, 2020
- Why Test for Proportional Hazards?JAMA, 2020
- Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery diseaseAmerican Heart Journal, 2012
- The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubtStatistics in Medicine, 2011
- Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectorisThe Lancet, 1992
- Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2JACC, 1988
- A Randomized, Controlled Trial of Aspirin in Persons Recovered From Myocardial InfarctionJAMA, 1980